Ikram Din Ujjan

TL;DR: In this article, a prospective, randomized, controlled, and open-label study, a daily dose of 1000 mg of quercetin was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease.

TL;DR: Taking into considerations its anti-inflammatory and thrombin-inhibitory actions, a bioavailable form of quercetin, like Quercet in Phytosome®, should be considered a possible candidate to clinically face COVID-19.

TL;DR: Although the authors found a high rate of MERS-CoV antibody positive dromedaries in Pakistan, no neutralizing antibodies were detected in humans with and without contact to camels, and the highest seroprevalence was recorded in camels aged > 10 years, followed by those aged 3.1–10 years and ≤ 3 years.

TL;DR: This is the first case control study describing the protective role of F5:c.6665A > G against preeclampsia in any world population and confirmed the association and role of MTHFR gene variations in the development of preeclampedia in Pakistani patients.

TL;DR: Following the publication of this article [1], the authors noted the following typographical errors.